Quality of Care

In Episode 68 of Unscripted, the AMCP podcast, pediatric gastroenterologist Dr. Jason Dranove of Atrium Health Levine Children's Hospital joins guest host Jessica Fann of Vanderbilt Specialty Pharmacy to explain how the two conditions differ, why standard laxatives often fall short on pain and incontinence, and what the expanded pediatric indication for Linzess (linaclotide) means for patients, providers, and managed care. AMCP produces Unscripted to connect managed care pharmacy professionals with the clinicians and evidence behind treatment and access decisions.

We’re excited to announce that the ARI–Lilly Medication Therapy Management (MTM) MIND project is moving from planning to implementation! Over the past several months, the project team and expert advisors have worked together to develop patient education materials, pharmacist training resources, brain health tools, and implementation workflows designed to help adults ages 40-60 understand and address risk factors associated with dementia.

The Academy of Managed Care Pharmacy (AMCP), in partnership with the AMCP Research Institute, published the 2025 edition of its annual Access, Affordability, and Outcomes: The Value of Managed Care Pharmacy report, which provides an in-depth look at how managed care pharmacy practices improve patient health outcomes, control prescription drug spending, and promote affordability for millions of Americans.

As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.

As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.

In AMCP's latest comments to the FDA, we emphasize the need for standardized public reporting of confirmatory trial progress, ensuring payers and health care providers have the necessary data to make informed coverage decisions. By supporting proactive communication and rigorous confirmatory trials, AMCP aims to balance early access to innovative treatments with patient safety and long-term therapeutic value.

Download the AMCP Engagement Framework at AMCP.org for Payers and Patient Organizations to find various resources, tools, examples, and instructions to guide payers and patient organizations in opening lines of communication to assist with incorporating the patient’s voice in decision-making processes.